Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Identifieur interne : 000C63 ( Main/Exploration ); précédent : 000C62; suivant : 000C64Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Auteurs : RBID : pubmed:23226020English descriptors
- KwdEn :
- Animals, Antineoplastic Agents (administration & dosage), Antineoplastic Agents (chemistry), Crystallization (methods), Female, Indium (diagnostic use), Isotope Labeling, Liposomes (chemistry), Materials Testing, Mice, Mice, Inbred C57BL, Mice, Nude, Nanocapsules (chemistry), Neoplasms, Experimental (drug therapy), Neoplasms, Experimental (metabolism), Neoplasms, Experimental (radionuclide imaging), Oligopeptides (administration & dosage), Oligopeptides (chemistry), Oligopeptides (pharmacokinetics), Organ Specificity, Polyethylene Glycols (chemistry), Radiopharmaceuticals (diagnostic use), Tissue Distribution.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Oligopeptides.
- chemical , chemistry : Antineoplastic Agents, Liposomes, Nanocapsules, Oligopeptides, Polyethylene Glycols.
- chemical , diagnostic use : Indium, Radiopharmaceuticals.
- drug therapy : Neoplasms, Experimental.
- metabolism : Neoplasms, Experimental.
- methods : Crystallization.
- chemical , pharmacokinetics : Oligopeptides.
- radionuclide imaging : Neoplasms, Experimental.
- Animals, Female, Isotope Labeling, Materials Testing, Mice, Mice, Inbred C57BL, Mice, Nude, Organ Specificity, Tissue Distribution.
Abstract
Liposomes have been proposed to be a means of selectively targeting cancer sites for diagnostic and therapeutic applications. The focus of this work was the evaluation of radiolabeled PEGylated liposomes derivatized with varying amounts of a cyclic arginyl-glycyl-aspartic acid (RGD) peptide. RGD peptides are known to bind to α(v)β(3) integrin receptors overexpressed during tumor-induced angiogenesis.
DOI: 10.2147/IJN.S36847
PubMed: 23226020
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.</title><author><name sortKey="Rangger, Christine" uniqKey="Rangger C">Christine Rangger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, Innsbruck Medical University, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Nuclear Medicine, Innsbruck Medical University</wicri:regionArea></affiliation></author><author><name sortKey="Helbok, Anna" uniqKey="Helbok A">Anna Helbok</name></author><author><name sortKey="Von Guggenberg, Elisabeth" uniqKey="Von Guggenberg E">Elisabeth von Guggenberg</name></author><author><name sortKey="Sosabowski, Jane" uniqKey="Sosabowski J">Jane Sosabowski</name></author><author><name sortKey="Radolf, Thorsten" uniqKey="Radolf T">Thorsten Radolf</name></author><author><name sortKey="Prassl, Ruth" uniqKey="Prassl R">Ruth Prassl</name></author><author><name sortKey="Andreae, Fritz" uniqKey="Andreae F">Fritz Andreae</name></author><author><name sortKey="Thurner, Gudrun C" uniqKey="Thurner G">Gudrun C Thurner</name></author><author><name sortKey="Haubner, Roland" uniqKey="Haubner R">Roland Haubner</name></author><author><name sortKey="Decristoforo, Clemens" uniqKey="Decristoforo C">Clemens Decristoforo</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.2147/IJN.S36847</idno><idno type="RBID">pubmed:23226020</idno><idno type="pmid">23226020</idno><idno type="wicri:Area/Main/Corpus">000900</idno><idno type="wicri:Area/Main/Curation">000900</idno><idno type="wicri:Area/Main/Exploration">000C63</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Agents (chemistry)</term><term>Crystallization (methods)</term><term>Female</term><term>Indium (diagnostic use)</term><term>Isotope Labeling</term><term>Liposomes (chemistry)</term><term>Materials Testing</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Nude</term><term>Nanocapsules (chemistry)</term><term>Neoplasms, Experimental (drug therapy)</term><term>Neoplasms, Experimental (metabolism)</term><term>Neoplasms, Experimental (radionuclide imaging)</term><term>Oligopeptides (administration & dosage)</term><term>Oligopeptides (chemistry)</term><term>Oligopeptides (pharmacokinetics)</term><term>Organ Specificity</term><term>Polyethylene Glycols (chemistry)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term><term>Oligopeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antineoplastic Agents</term><term>Liposomes</term><term>Nanocapsules</term><term>Oligopeptides</term><term>Polyethylene Glycols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms, Experimental</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neoplasms, Experimental</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Crystallization</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Oligopeptides</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Neoplasms, Experimental</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Isotope Labeling</term><term>Materials Testing</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Nude</term><term>Organ Specificity</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Liposomes have been proposed to be a means of selectively targeting cancer sites for diagnostic and therapeutic applications. The focus of this work was the evaluation of radiolabeled PEGylated liposomes derivatized with varying amounts of a cyclic arginyl-glycyl-aspartic acid (RGD) peptide. RGD peptides are known to bind to α(v)β(3) integrin receptors overexpressed during tumor-induced angiogenesis.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23226020</PMID><DateCreated><Year>2012</Year><Month>12</Month><Day>11</Day></DateCreated><DateCompleted><Year>2013</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1178-2013</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>International journal of nanomedicine</Title><ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation></Journal><ArticleTitle>Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.</ArticleTitle><Pagination><MedlinePgn>5889-900</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S36847</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Liposomes have been proposed to be a means of selectively targeting cancer sites for diagnostic and therapeutic applications. The focus of this work was the evaluation of radiolabeled PEGylated liposomes derivatized with varying amounts of a cyclic arginyl-glycyl-aspartic acid (RGD) peptide. RGD peptides are known to bind to α(v)β(3) integrin receptors overexpressed during tumor-induced angiogenesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Several liposomal nanoparticles carrying the RGD peptide targeting sequence (RLPs) were synthesized using a combination of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, cholesterol, diethylenetriaminepentaacetic acid-derivatized lipids for radiolabeling, a polyethylene glycol (PEG) building block, and a lipid-based RGD building block. Relative amounts of RGD and PEG building blocks were varied. In vitro binding affinities were determined using isolated α(v)β(3) integrin receptors incubated with different concentrations of RLPs in competition with iodine-125-labeled cyclo-(-RGDyV-). Binding of the indium-111-labeled RLPs was also evaluated. Biodistribution and micro single photon emission computed tomography/computed tomography imaging studies were performed in nude mice using different tumor xenograft models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">RLPs were labeled with indium-111 with high radiochemical yields. In vitro binding studies of RLPs with different RGD/PEG loading revealed good binding to isolated receptors, which was dependent on the extent of RGD and PEG loading. Binding increased with higher RGD loading, whereas reduced binding was found with higher PEG loading. Biodistribution showed increased circulating time for PEGylated RLPs, but no dependence on RGD loading. Both biodistribution and micro single photon emission computed tomography/computed tomography imaging studies revealed low, nonspecific tumor uptake values.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this study, RLPs for targeting angiogenesis were described. Even though good binding to α(v)β(3) integrin receptors was found in vitro, the balance between PEGylation and RGD loading clearly requires optimization to achieve targeting in vivo. These data form the basis for future development and provide a platform for the investigation of multimodal approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rangger</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Affiliation>Department of Nuclear Medicine, Innsbruck Medical University, Austria.</Affiliation></Author><Author ValidYN="Y"><LastName>Helbok</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>von Guggenberg</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sosabowski</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Radolf</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Prassl</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Andreae</LastName><ForeName>Fritz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Thurner</LastName><ForeName>Gudrun C</ForeName><Initials>GC</Initials></Author><Author ValidYN="Y"><LastName>Haubner</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Decristoforo</LastName><ForeName>Clemens</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Nanomedicine</MedlineTA><NlmUniqueID>101263847</NlmUniqueID><ISSNLinking>1176-9114</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Nanocapsules</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>045A6V3VFX</RegistryNumber><NameOfSubstance>Indium</NameOfSubstance></Chemical><Chemical><RegistryNumber>31JB8MKF8Z</RegistryNumber><NameOfSubstance>indium trichloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>99896-85-2</RegistryNumber><NameOfSubstance>arginyl-glycyl-aspartic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mol Biosyst. 2010 May;6(5):878-87</RefSource><PMID Version="1">20567774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2010 Jan;10(1):9-22</RefSource><PMID Version="1">20029421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Liposome Res. 2010 Sep;20(3):219-27</RefSource><PMID Version="1">19863193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Angew Chem Int Ed Engl. 2010 Aug 23;49(36):6288-308</RefSource><PMID Version="1">20648499</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Biopharm. 2010 Oct;76(2):170-8</RefSource><PMID Version="1">20600887</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2011 Feb 22;5(2):738-47</RefSource><PMID Version="1">21275414</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ChemMedChem. 2011 Apr 4;6(4):678-85</RefSource><PMID Version="1">21370475</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5</RefSource><PMID Version="1">20304019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Mater. 2011 May;10(5):389-97</RefSource><PMID Version="1">21499315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2011 Jun 15;411(1-2):206-14</RefSource><PMID Version="1">21443937</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2011 Dec 5;8(6):2101-41</RefSource><PMID Version="1">21974749</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Nanomedicine. 2011;6:3087-98</RefSource><PMID Version="1">22163162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nanomedicine. 2012 Jan;8(1):112-8</RefSource><PMID Version="1">21645641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Analyst. 2012 Feb 7;137(3):773-86</RefSource><PMID Version="1">22158519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2012 Apr 15;426(1-2):170-81</RefSource><PMID Version="1">22266537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharm Sci. 2012 Jun 14;46(3):121-30</RefSource><PMID Version="1">22381076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2012 Jun 10;160(2):254-63</RefSource><PMID Version="1">22245688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Protein Eng Des Sel. 2004 May;17(5):433-41</RefSource><PMID Version="1">15235124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 2000 Jun;52(2):237-68</RefSource><PMID Version="1">10835101</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2000 Jun;293(3):996-1001</RefSource><PMID Version="1">10869403</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Lipid Res. 2000 Sep;39(5):461-75</RefSource><PMID Version="1">11082507</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2001 Feb;7(2):223-5</RefSource><PMID Version="1">11234871</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2001 Mar 1;61(5):1781-5</RefSource><PMID Version="1">11280722</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Biol Ther. 2001 Nov;1(6):923-47</RefSource><PMID Version="1">11728226</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2002 Jan 17;78(1-3):235-47</RefSource><PMID Version="1">11772464</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2004 Mar 19;303(5665):1818-22</RefSource><PMID Version="1">15031496</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucl Med Biol. 2004 May;31(4):441-9</RefSource><PMID Version="1">15093814</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ACS Nano. 2011 Jul 26;5(7):5552-9</RefSource><PMID Version="1">21657210</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Colloids Surf B Biointerfaces. 2012 Jan 1;89:93-100</RefSource><PMID Version="1">21962853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Nanomedicine. 2011;6:2607-19</RefSource><PMID Version="1">22114492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Biol. 1965 Aug;13(1):238-52</RefSource><PMID Version="1">5859039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57</RefSource><PMID Version="1">637870</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1982 Feb;69(2):263-9</RefSource><PMID Version="1">6460044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Exp Rheumatol. 1985 Jul-Sep;3(3):237-42</RefSource><PMID Version="1">4053442</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1991 Jan 3;324(1):1-8</RefSource><PMID Version="1">1701519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 1991 Jun 24;284(2):263-6</RefSource><PMID Version="1">2060647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 1992 Jun;6(9):2716-9</RefSource><PMID Version="1">1612296</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biophys J. 1998 Mar;74(3):1371-9</RefSource><PMID Version="1">9512033</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharm Pharm Sci. 2005;7(4):29-34</RefSource><PMID Version="1">15850546</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2005 Mar;2(3):e70</RefSource><PMID Version="1">15783258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Dec 15;438(7070):967-74</RefSource><PMID Version="1">16355214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 2006 Jul-Aug;26(4B):2841-8</RefSource><PMID Version="1">16886603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Chem. 2006 Oct 5;49(20):6087-93</RefSource><PMID Version="1">17004722</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucl Med Biol. 2007 Feb;34(2):165-71</RefSource><PMID Version="1">17307124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2007 Aug;322(2):560-8</RefSource><PMID Version="1">17510318</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Magn Reson Imaging. 2007 Aug;26(2):235-49</RefSource><PMID Version="1">17623889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Yakugaku Zasshi. 2007 Sep;127(9):1497-501</RefSource><PMID Version="1">17827930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Pharm. 2007 Nov 1;344(1-2):110-7</RefSource><PMID Version="1">17592745</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1100-8</RefSource><PMID Version="1">18204838</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Drug Target. 2009 Jan;17(1):10-8</RefSource><PMID Version="1">19016068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Control Release. 2010 Aug 3;145(3):178-81</RefSource><PMID Version="1">20338200</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Crystallization</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Isotope Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liposomes</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Materials Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Nanocapsules</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms, Experimental</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName MajorTopicYN="N">chemistry</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3512544</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RGD peptides</Keyword><Keyword MajorTopicYN="N">angiogenesis</Keyword><Keyword MajorTopicYN="N">liposomes</Keyword><Keyword MajorTopicYN="N">tumor targeting</Keyword><Keyword MajorTopicYN="N">αvβ3 integrin receptors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="epublish"><Year>2012</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S36847</ArticleId><ArticleId IdType="pii">ijn-7-5889</ArticleId><ArticleId IdType="pubmed">23226020</ArticleId><ArticleId IdType="pmc">PMC3512544</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23226020
|texte= Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23226020" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |